152 related articles for article (PubMed ID: 15179523)
1. [Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].
Thiele J; Kvasnicka HM; Varus E; Kriener S; Engels K; Staib P; Ollig ES; Griesshammer M; Waller CF; Pfeifer H; Schmitt-Gräff A
Pathologe; 2004 Nov; 25(6):428-35. PubMed ID: 15179523
[TBL] [Abstract][Full Text] [Related]
2. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
[TBL] [Abstract][Full Text] [Related]
3. Megakaryocytes carry the fused bcr-abl gene in chronic myeloid leukaemia: a fluorescence in situ hybridization analysis from bone marrow biopsies.
Nolte M; Werner M; Ewig M; von Wasielewski R; Link H; Diedrich H; Georgii A
Virchows Arch; 1996 Mar; 427(6):561-5. PubMed ID: 8605566
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in-situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon-alpha therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation.
Thiele J; Schmitz B; Gross H; Kvasnicka HM; Niederle N; Leder LD; Fischer R
Histopathology; 1997 Sep; 31(3):215-21. PubMed ID: 9354890
[TBL] [Abstract][Full Text] [Related]
6. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
[TBL] [Abstract][Full Text] [Related]
7. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
8. Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Kriener S; Engels K; Staib P; Griesshammer M; Waller CF; Ottmann OG; Hansmann ML
Histol Histopathol; 2004 Oct; 19(4):1277-88. PubMed ID: 15375771
[TBL] [Abstract][Full Text] [Related]
9. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
11. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
13. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
[TBL] [Abstract][Full Text] [Related]
14. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
15. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
16. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
[TBL] [Abstract][Full Text] [Related]
17. [Chronic myeloid leukemia--update].
Tobler A; Solenthaler M
Ther Umsch; 2004 Feb; 61(2):143-50. PubMed ID: 15018397
[TBL] [Abstract][Full Text] [Related]
18. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
[TBL] [Abstract][Full Text] [Related]
19. Molecular cytogenetics of chronic myeloid leukemia with atypical t(6;9) (p23;q34) translocation.
Jadayel D; Calabrese G; Min T; van Rhee F; Swansbury GJ; Dyer MJ; Maitland J; Palka G; Catovsky D
Leukemia; 1995 Jun; 9(6):981-7. PubMed ID: 7596189
[TBL] [Abstract][Full Text] [Related]
20. Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens.
Werner M; Ewig M; Nasarek A; Wilkens L; von Wasielewski R; Tchinda J; Nolte M
Diagn Mol Pathol; 1997 Oct; 6(5):282-7. PubMed ID: 9458387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]